Page last updated: 2024-12-07

cleistanthin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cleistanthin B is a diterpenoid compound isolated from the plant *Cleistanthus collinus*. It has shown promising biological activities, including cytotoxic, antibacterial, and antifungal properties. The compound has been shown to inhibit the growth of various cancer cell lines, including leukemia, breast cancer, and colon cancer cells. Researchers are interested in Cleistanthin B due to its potential as a lead compound for the development of new anticancer drugs. Studies have focused on understanding its mechanism of action and exploring its potential in combination therapies. Further research is underway to evaluate its safety and efficacy in preclinical and clinical trials.'

cleistanthin B: toxic constituent of Cleistanthus collinus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cleistanthin B : A member of the class of cleistanthins that is cleistanthin A in which the 3,4-di-O-methyl-D-xylopyranosyl group is replaced by a beta-D-glucopyranosyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Cleistanthusgenus[no description available]Phyllanthaceae[no description available]
Cleistanthus collinusspecies[no description available]Phyllanthaceae[no description available]

Cross-References

ID SourceID
PubMed CID119458
CHEMBL ID601587
CHEBI ID84407
MeSH IDM0209892

Synonyms (20)

Synonym
30021-77-3
cleistanthin b
chebi:84407 ,
gnf-pf-349 ,
CHEMBL601587
9-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3h-benzo[f][2]benzofuran-1-one
naphtho(2,3-c)furan-1(3h)-one, 9-(1,3-benzodioxol-5-yl)-4-(beta-d-glucopyranosyloxy)-6,7-dimethoxy-
clei b
9-(1,3-benzodioxol-5-yl)-4-(beta-d-glucopyranosyloxy)-6,7-dimethoxynaphtho(2,3-c)furan-1(3h)-one
4-o-(beta-d-glucopyranosyl)diphyllin
9-(1,3-benzodioxol-5-yl)-4-(beta-d-glucopyranosyloxy)-6,7-dimethoxynaphtho[2,3-c]furan-1(3h)-one
9-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-1-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl beta-d-glucopyranoside
diphyllin beta-d-glucoside
Q27157736
diphyllin o-glucoside
DTXSID501014455
MS-29983
HY-N9351
CS-0159499
AKOS040735117

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cleistanthinsAny of the lignans with a 9-aryl-1-oxo-1,3-dihydronaphtho[2,3-c]furan-4-yl glycoside skeleton originally isolated from Cleistanthus collinus, a toxic deciduous shrub. While all parts of the plant are poisonous, the leaves in particular are used as a suicide poison by young women in rural parts of southern India. Cleistanthins A and B have been particularly associated with the toxicity of the plant, with cleistanthin A being more potent than cleistanthin B.
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID634827Inhibition of human topoisomerase 2-mediated decatenation of kinetoplast DNA at 100 uM after 15 mins by agarose gel electrophoresis2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID634820Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID1224607Cytotoxicity against human HT-29 cells2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID634821Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1224608Cytotoxicity against human CCD-112CoN cells2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.
AID1377181Antiviral activity against HIV1 virions derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed virions followed by incubation with target cel2017Journal of natural products, 06-23, Volume: 80, Issue:6
Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa.
AID634819Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (22.22)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]